About
Nuvisan provides contract research and development services for drug discovery, preclinical development, clinical trials, and clinical trial supply. It serves pharmaceutical and biotech clients from sites in Germany, France, and India.
Services
Omics and biomarkers
Supports target identification and validation, mode-of-action studies, compound profiling, and pharmacodynamic and predictive biomarker discovery.
Functional genomics and next-generation sequencing
Provides CRISPR/Cas9, RNA interference, NGS, single-cell sequencing, and bioinformatics for functional studies and target discovery.
Biosciences
Offers protein production, biochemical assays, cell-based assays, high-content analysis, biophysics, mass spectrometry, and structural biology support for hit identification and characterisation.
Compound screening
Runs high-throughput screening to identify first hits against client-specific targets and mechanisms.
Pharmacology
Delivers in vivo pharmacology models to generate efficacy and safety data for drug development.
Chemistry
Supports hit-to-lead, lead optimisation, scale-up, biotransformations, and physicochemical characterisation.
Development DMPK
Provides in vitro and in vivo DMPK and ADME services, metabolite identification, isotope chemistry, and bioanalysis.
ADME, DMPK & toxicology
In vitro DMPK
Performs assays for metabolic stability, drug-drug interactions, metabolite identification, permeability and transporters, and protein binding.
ADME, DMPK & toxicology
15 more services
- Metabolite ID
- Preclinical development
- Clinical services phase 1-2
- Clinical pharmacology unit
- Clinical laboratory
- Clinical trial supply services
- Manufacturing of IMP
- Digital science technologies
- Cheminformatics and machine learning
- Discovery services
- Pharmaceutical analytical services
- Drug substances
- Drug products
- Bioanalysis
- Biomarkers
- What to send
- Sample barcoding
Capabilities
- Assays and studies
- Bioanalysis
- Stability studies
- CRISPR
- ADME
- Toxicology
- In vivo
21 more
- HTS
- Small molecules
- High-throughput screening
- Biochemical assays
- Cell-based assays
- High-content assays
- Biophysics assays
- Protein binding assays
- Drug-drug interaction assays
- Metabolic stability assays
- Permeability assays
- Transporter assays
- Metabolite identification
- In vivo efficacy studies
- PK/PD studies
- Clinical safety lab analyses
- Fragment screening
- Virtual screening
- Biophysical analyses
- Structure-based design
- CRISPR/Cas9
- Scale and capacity
- 40 high-monitoring beds
- 60 overnight beds
- Up to 100 L fermenters
- 4-16 L wave bioreactors
- Semi-solid clinical batches up to 50 kg
- Proprietary small molecule library up to 3 million compounds
3 more
- More than 5.000 m² GMP facilities
- More than 320 m² of stability storage
- Six full-time qualified persons
- Therapeutic areas
- Oncology
- Dermatology
Instruments and platforms
- 10x Genomics
- ClinSpark
- ÄKTA
- SPR
- MST
- ITC
- NMR
- nanoDSF
- TSA
- SEC-MALS
- DLS
- F-SEC
- Flow cytometry
- MS
- HR-MS
- Electronic lab notebook
- LIMS
Modalities and species
- Modalities
- Small molecule
- Antibody
- ADC
- Peptide
- Gene editing
- Recombinant protein
- Vaccine
- Biosimilar
- Species and models
- Rodent
- Non-rodent species
- Healthy volunteers
- Special populations
- Patients
- iPSC-derived cells
11 more
- Primary cells
- Cell lines
- E. coli
- Insect cells
- Mammalian cells
- CHO
- HEK293
- Expi293F
- Tni
- Tumour-bearing animal models
- In vivo models
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
GLPSelf-reported
Scope: laboratories
Details
- Type
- CRDMO
- Team
- More than 100 analytical experts across Europe
- Address
- Wegenerstrasse 13 89231 Neu-Ulm Germany Berlin Muellerstrasse 178 13353 Berli
- Sites
- Berlin, Germany · Sophia Antipolis, France · Grafing, Germany · Waltrop, Germany · Hyderabad, India
- Serves
- Global, worldwide, Europe